BioCentury
ARTICLE | Company News

Basilea bolsters board

November 30, 2011 1:45 AM UTC

Shareholders of Basilea Pharmaceutica AG (SIX:BSLN) elected three additional directors to the biotech's five-member board Tuesday at a meeting requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG (Basel, Switzerland); Domenico Scala, formerly CEO of dental implant company Nobel Biocare Holding AG (SIX:NOBN); and Thomas Werner, former managing director and SVP of the German unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). On Tuesday, Basilea was off CHF0.10 to CHF30. ...